Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

HuGENet Review
N-Acetyltransferase Polymorphisms and Colorectal Cancer
N. Brockton, J. Little, L. Sharp, and S.C. Cotton
back to review

 REFERENCES
  1. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochemical and Biophysical Research Communications 1991;177:1252-7.
  2. Blum M, Grant DM, McBride W, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA and Cell Biology 1990;9:193-203.
  3. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochemical Journal 1994;297:441-5.
  4. Smith CAD, Smith G, Wolf CR. Genetic polymorphisms in xenobiotic metabolism. European Journal of Cancer 1994;30A:1921-1935.
  5. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
  6. Sinha R, Rothman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Research 1994;54:6154-9.
  7. Lang NP, Chu DZJ, Hunter CF, et al. Role of aromatic amine acetyltransferase in human colorectal cancer. Archives of Surgery 1986;121:1259-61.
  8. Rodriguez JW, Kirlin WG, Ferguson RJ, et al. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Archives of Toxicology 1993;67:445-52.
  9. Hickman D, Pope J, Patil SD, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998;42:402-9.
  10. Bönicke R, Reif W. Enzymatic inactivation of isonicotinic acid hydrazide in humans and animals. Arch Exp Pathol Pharmak 1953;220:321-33.
  11. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. British Medical Journal 1960;2:485-91.
  12. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of United States of America 1991;88:5237-41.
  13. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. Journal of Biological Chemistry 1990;265:4630-4.
  14. Lin HJ, Han CY, Lin BK, et al. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: Application to metabolic epidemiology. American Journal of Human Genetics 1993;52:827-34.
  15. Woolhouse NM, Qureshi MM, Bayoumi RAL. A new mutation C759T in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1997;7:83-4.
  16. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-92.
  17. Deloménie C, Goodfellow GH, Krishnamoorthy R, et al. Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochemical Journal 1997;323:207-15.
  18. Lin HJ, Han CY, Lin BK, et al. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-34.
  19. Cascorbi I, Brockmöller J, Bauer S, et al. NAT2*12A (803A®G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 1996;6:257-9.
  20. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Research 1995;55:3531-3536.
  21. Smith CAD, Wadelius M, Gough AC, et al. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. Journal of Medical Genetics 1997;34:758-60.
  22. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1993;3:209-12.
  23. Butcher N, Ilett K, Minchin R. Intra- and inter-individual differences in N-acetyltransferase type 1 activity in human peripheral blood mononuclear cells. Proceedings of the American Association for Cancer Research 1997;38:338.
  24. Lin HJ, Probst-Hensch NM, Hughes NC, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 1998;8:269-81.
  25. Bell DA, Stephens EA, Castranio T, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Research 1995;55:3537-42.
  26. Hughes NC, Janezic SA, McQueen KL, et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogentics 1998; 8:55-56.
  27. Deloménie C, Sica L, Grant DM, et al. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996;6:177-85.
  28. Martínez C, Agúndez JAG, livera M, et al. Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population. Clinical Pharmacology and Therapeutics 1998;63:623-8.
  29. Hunter DJ, Hankinson SE, Hough H, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 1997;18:2127-32.
  30. Probst-Hensch NM, Haile RW, Li DS, et al. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996;17:2125-9.
  31. Potter JD, Bigler J, Fosdick L, et al. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiology, Biomarkers and Prevention 1999;8:69-75.
  32. Ambrosone CB, Freudenheim JL, Graham S, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. Journal of the American Medical Association 1996;276:1494-501.
  33. Mendola P, Moysich KB, Freudenheim JL, et al. Risk of recurrent spontaneous abortion, cigarette smoking, and genetic polymorphisms in NAT2 and GSTM1. Epidemiology 1998;9:666-8.
  34. Hirvonen A, Taylor JA, Wilcox A, et al. Xenobiotic metabolism genes and the risk of recurrent spontaneous abortion. Epidemiology 1996;7:206-8.
  35. Millikan RC, Pittman GS, Newman B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiology, Biomarkers and Prevention 1998;7:371-8.
  36. Trizna Z, de Andrade M, Kyritsis AP, et al. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiology, Biomarkers and Prevention 1998;7:553-5.
  37. Slattery ML, Potter JD, Samowitz W, et al. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiology, Biomarkers and Prevention 1998;7:1079-84.
  38. Chen J, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Research 1998;58:3307-11.
  39. Rothman N, Talaska G, Hayes RB, et al. Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiology, Biomarkers and Prevention 1997;6:1039-42.
  40. Shibuta K, Nakashima T, Abe M, et al. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 1994;74:3108-12.
  41. Asada M, Goto H, Abe M, et al. N-Acetylation polymorphism in Japanese patients with sarcoidosis. Pharmacogenetics 1997;7:341-4.
  42. Katoh T, Kaneko S, Boissy R, et al. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 1998;19:1803-7.
  43. Okumura K, Kita T, Chikazawa S, et al. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clinical Pharmacology and Therapeutics 1997;61:509-17.
  44. Oyama T, Kawamoto T, Mizoue T, et al. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Research 1997;17:577-82.
  45. Morita S, Yano M, Tsujinaka T, et al. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. International Journal of Cancer 1998;79:517-20.
  46. Zhao B, Lee EJD, Wong JYY, et al. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Pharmacogenetics 1995;5:275-80.
  47. Lee EJD, Zhao B, Seow-Choen F. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. Pharmacogenetics 1998;8:513-7.
  48. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, et al. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 1997;7:327-31.
  49. Woolhouse NM, Qureshi MM, Bastaki SMA, et al. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics 1997;7:73-82.
  50. Nielsen PS, de Pater N, Okkels H, et al. Environmental air pollution and DNA adducts in Copenhagen bus drivers – Effect of GSMT1 and NAT2 genotypes on adduct levels. Carcinogenesis 1996;17:1021-7.
  51. Okkels H, Sigsgaard T, Wolf H, et al. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiology, Biomarkers and Prevention 1997;6:225-31.
  52. Muiras ML, Verasdonck P, Cottet F, et al. Lack of association between human logevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Human Genetics 1998;102:526-32.
  53. Bendriss EK, Bechtel YC, Paintaud G, et al. Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes. Pharmacogenetics 1998;8:201-9.
  54. Bouchardy C, Mitrunen K, Wikman H, et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-8.
  55. Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated caucasian individuals: correlation with phenotypic activity. American Journal of Human Genetics 1995;57:581-92.
  56. Schnakenberg E, Ehiers C, Feyerabend W, et al. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clinical Genetics 1998;53:396-402.
  57. Cascorbi I, Brockmoller J, Mrozikiewicz PM, et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Research 1996;56:3961-6.
  58. Brockmöller J, Cascorbi I, Kerb R, et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Research 1996;56:3915-25.
  59. Bartsch H, Malaveille C, Lowenfels AB, et al. Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. European Journal of Cancer Prevention 1998;7:215-23.
  60. Gabbani G, Nardini B, Bordin A, et al. Urinary mutagenicity on TA98 and YG1024 Salmonella typhimurium strains after a hamburger meal: influence of GSTM1 and NAT2 genotypes. Mutagenesis 1998;13:187-91.
  61. Dallinga JW, Pachen DM, Wijnhoven SW, et al. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiology, Biomarkers and Prevention 1998;7:571-7.
  62. Zielinska E, Niewiarowski W, Bodalski J, et al. Arylamine N-acetyltransferase (NAT2 ) gene mutations in children with allergic diseases. Clinical Pharmacology and Therapeutics 1997;62:635-42.
  63. Mrozikiewicz PM, Cascorbi I, Brockmoller J, et al. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clinical Pharmacology and Therapeutics 1996;59:376-82.
  64. Zielinska E, Niewiarowski W, Bodalski J, et al. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants. Pharmacy World and Science 1998;20:123-30.
  65. Lemos MC, Fegateiro FJ. N-acetyltransferase genotypes in the Portuguese population. Pharmacogenetics 1998;8:561-4.
  66. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998; 19:37-41.
  67. Kalina I, Gajdosová D, Binková B, et al. Cytogenic monitoring in coke oven workers. Mutation Research 1998;417:9-17.
  68. Binková B, Topinka J, Mracková G, et al. Coke oven workers study: the effect of exposure and GSTM1 and NAT2 genotypes on DNA adduct levels in white blood cells and lymphocytes as determined by 32P-postlabelling. Mutation Research 1998;416:67-84.
  69. Agúndez JAG, Ladero JM, Olivera M, et al. Genetic analysis of the arylamine N-Acetyltransferase polymorphism in breast cancer patients. Oncology 1995;52:7-11.
  70. Martinez C, Agúndez JAG, Olivera M, et al. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995;5:207-14.
  71. Agúndez JAG, Olivera M, Ladero JM, et al. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996;6:501-12.
  72. Agúndez JAG, Menaya JG, Tejeda R, et al. Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Pharmacogenetics 1996;6:465-72.
  73. Agúndez JAG, Rodríguez I, Olivera M, et al. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age and Ageing 1997;26:147-51.
  74. Agúndez JAG, Martinez C, Olivera M, et al. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. British Journal of Cancer 1998;78:1356-60.
  75. Agúndez JAG, Jiménez-Jiménez FJ, Luengo A, et al. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 1998;51:1587-92.
  76. Dalene M, Jakobsson K, Rannug A, et al. MDA in plasma as a biomarker of exposure to pyrolysed MDI-based polyurethane: correlations with estimated cumulative dose and genotype for N-acetylation. International Archives of Occupational and Environmental Health 1996;68:165-9.
  77. Nyberg F, Hou SM, Hemminki K, et al. Glutathione S-Transferase m1 and N-Acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiology, Biomarkers and Prevention 1998;7:875-83.
  78. Hubbard AL, Harrison DJ, Moyes C, et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut 1997;41:229-34.
  79. Bandmann O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997;350:1136-9.
  80. Risch A, Smelt V, Lane D, et al. Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Pharmacology and Toxicology 1996;78:235-40.
  81. Welfare MR, Cooper J, Bassendine MF, et al. Relationship between acetylator status, smoking, diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997;18:1351-4.
  82. Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of isoniazid elimination. Phenotype and genotype in patients with tuberculosis. American Journal of Respiratory and Critical Care Medicine 1997;155:1717-22.
  83. Kirlin WG, Ogolla F, Andrews AF, et al. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients. Cancer Research 1991;51:549-55.
  84. Rothman N, Bhatnagar VK, Hayes RB, et al. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial NDA adducts in exposed workers. Proceedings of the National Academy of Sciences of United States of America 1996;93:5084-9.
  85. Koizumi A, Nomlyama T, Tsukada M, et al. Evidence on N-acetyltransferase allele-associated metabolism of hydrazine in Japanese workers. Journal of Occupational and Environmental Medicine 1998;40:217-22.
  86. Bulovskaya LN, Krupkin RG, Bochina TA, et al. Acetylator phenotype in patients with breast cancer. Oncology 1978;35:185-8.
  87. Sardas S, Çok I, Sardas OS, et al. Polymorphic N-acetylation capacity in breast cancer patients. International Journal of Cancer 1990;46:1138-9.
  88. Schnuch A, Wstphal GA, Müller MM, et al. Genotype and phenotype of N-acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy. Contact Dermatitis 1998;38:209-11.
  89. Ladero JM, Fernández MJ, Palmeiro R, et al. Hepatic acetylator polymorphism in breast cancer patients. Oncology 1987;44:341-4.
  90. Ladero JM, González JF, Benítez J, et al. Acetylator polymorphism in human colorectal carcinoma. Cancer Research 1991;51:2098-100.
  91. Webster DJT, Flook D, Jenkins J, et al. Drug acetylation in breast cancer. British Journal of Cancer 1989;60:236-7.
  92. Cartwright RA, Glashan RW, Rogers HJ, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;2:842-6.
  93. Philip PA, Rogers HJ, Millis RR, et al. Acetylator status and its relationship to breast cancer and other diseases of the breast. European Journal of Cancer and Clinical Oncology 1987;23:1701-6.
  94. Ilett KF, Detchon P, Ingram DM, et al. Acetylation phenotype is not associated with breast cancer. Cancer Research 1990;50:6649-51.
  95. Hubbard AL, Moyes C, Wyllie AH, et al. N-acetyl transferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients. British Journal of Cancer 1998;77:913-6.
  96. WHO (World Health Organization). Conquering suffering, enriching humanity. Report No. WHO/WHR/97. Geneva: World Health Organization, 1997.
  97. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. International Journal of Cancer 1993;54:594-606.
  98. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Volume VII. Lyon: IARC, 1997.
  99. Coleman MP, Estève J, Damiecki P, et al. Trends in Cancer Incidence and Mortality. Lyon: IARC, 1993.
  100. Muir C, Waterhouse J, Mack T, et al. Cancer incidence in five continents. Volume V. Lyon: IARC, 1987.
  101. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. Journal of the National Cancer Institute 1995;87:1114-25.
  102. St. John DJB, McDermott FT, Hopper JL, et al. Cancer risk in relatives of patients with common colorectal cancer. Annals of Internal Medicine 1993;118:785-90.
  103. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer.  New England Journal of Medicine 1994;331:1669-74.
  104. Haenszel W, Kurihara M. Studies of Japanese migrants: mortality from cancer and other diseases among Japanese in the United States. Journal of the National Cancer Institute 1968;40:43-68.
  105. Schottenfeld D, Winawer SJ. Cancers of the large intestine. In Schottenfeld D, Fraumeni JF, Jr. eds. Cancer Epidemiology and Prevention. New York: Oxford University Press, 1996:813-40.
  106. World Cancer Research Fund in Association with American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: a global perspective. Menasha: American Institute for Cancer Research, 1997.
  107. Surgeon General. Physical Activity and Health. A Report of the Surgeon General.  Washington, D.C.: US Department of Health and Human Services. 1996.
  108. IARC Working Group. IARC Handbook of Cancer Prevention, Volume 1: Non-Steroidal Anti-Inflammatory Drugs. Lyon: IARC, 1997.
  109. Vineis P, McMichael A. Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer. Cancer Causes and Control 1996;7:479-86.
  110. Augustsson K, Skog K, Jägerstad M, et al. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet 1999;353:703-707.
  111. IARC Working Group. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans Volume 38. Tobacco Smoking. Lyon: IARC, 1986.
  112. Cotton S, Sharp L, Little J. The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia. Critical Reviews in Oncogenesis 1996;7(5&6):293-342.
  113. Giovannucci E, Rimm EB, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US men. Journal of the National Cancer Institute 1994;86:183-91.
  114. Giovannucci E, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in US women. Journal of the National Cancer Institute 1994;86:192-199.
  115. Heineman EF, Zahm SH, McLaughlin JK, et al. Increased risk of colorectal cancer among smokers: Results of a 26-year follow-up of US veterans and a review. International Journal of Cancer 1995;59:728-738.
  116. Knekt P, Hakama M, Jarvinen R, et al. Smoking and risk of colorectal cancer. British Journal of Cancer 1998;78:136-9.
  117. Nyren O, Bergstrom R, Nystrom L, et al. Smoking and colorectal cancer: a 20-year follow-up sudy of Swedish construction workers. Journal of the National Cancer Institute 1996;88:1302-1307.
  118. Wohlleb JC, Hunter CF, Blass B, et al. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. International Journal of Cancer 1990;46:22-30.
  119. Ilett KF, David BM, Detchon P, et al. Acetylation phenotype in colorectal carcinoma. Cancer Research 1987;47:1466-9.
  120. Roberts-Thomson IC, Ryan P, Khoo KK, et al. Diet, acetylator phenotype and risk of colorectal neoplasia. Lancet 1996;347:1372-4.
  121. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiology, Biomarkers and Prevention 1994;3:675-682.
  122. Oda Y, Tanaka M, Nakanishi I. Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. Carcinogenesis 1994;15:1365-9.
  123. Jenkins M, Bigler J, Kampman E, et al. Associations between colon cancer and acetylation (NAT1 and NAT2) genotypes in a large population-based study. American Journal of Epidemiology 1997;145:S68.
  124. Probst-Hensch NM, Haile RW, Ingles SA, et al. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Research 1995;55:2017-20.
  125. Lee E, Huang Y, Zhao B, et al. Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1; GSTT1; NAT1 and NAT2. Journal of Toxicology Sciences 1998;23:140-2.
  126. Kampman E, Slattery ML, Bigler J, et al. Meat consumption, genetic susceptibility, and colon cancer risk: A United States multicenter case-control study. Cancer Epidemiology, Biomarkers and Prevention 1999; 8:15-24.
  127. Bell DA, Badawi AF, Lang NP, et al. Polymorphism in the N-Acetyltransferase 1 (NAT1) Polyadenylation signal: Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Research 1995;55:5226-9.
  128. Meisel P, Schroeder C, Wulff K, et al. Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression: 1. Genotype and N-acetylation in vivo. Pharmacogenetics 1997;7:241-246.
  129. Hanna PE. Metabolic activation and detoxification of arylamines. Current Medicinal Chemistry 1996;3:195-210.
  130. Cotton SC, Sharp L, Little J, et al. Glutathione S Transferase polymorphisms and colorectal cancer: a review. American Journal of Epidemiology (in press).
  131. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
  132. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. Journal of Biochemistry 1999;125:803-808.
  133. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a C®A polymorphism in intron 1 of the cytrochrome P450 CYP1A2 gene tested with caffeine. British Journal of Clinical Pharmacology 1999;47:445-449.
  134. Bigler J, Chen C, Potter JD. Determination of human NAT2 acetylator genotype by oligonucleotide ligation assay. Biotechniques 1997;22:682-4.
Page last reviewed: May 1, 2000 (archived document)
Page last updated: November 2, 2007
Content Source: CDC's Office of Public Health Genomics